Sivan Elloul, PhD
Affiliations: | Pathology | Harvard Medical School - Beth Israel Deaconess Medical Center |
Google:
"Sivan Elloul"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dugast A, McArdel S, Hoover M, et al. (2019) Abstract 3272: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profile Cancer Research. 79: 3272-3272 |
| Farren MR, Hennessey RC, Shakya R, et al. (2017) The exportin-1 inhibitor selinexor exerts superior anti-tumor activity when combined with T cell checkpoint inhibitors. Molecular Cancer Therapeutics |
| Muqbil I, Aboukameel A, Elloul S, et al. (2016) Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Letters |
| Argueta C, Chang H, Kashyap T, et al. (2016) Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma Blood. 128: 3298-3298 |
| Elloul S, Depew C, Nerle S, et al. (2016) Engineered Erythrocytes As an Anti-Tumor Therapy through Induction of Apoptosis or Immune-Checkpoint Inhibition Blood. 128: 2166-2166 |
| Elloul S, Chang H, Klebanov B, et al. (2016) Abstract 4720: Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and panobinostat in a mouse model of multiple myeloma Cancer Research. 76: 4720-4720 |
| Elloul S, Chang HH, Klebanov B, et al. (2016) Abstract 4646: Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and trastuzumab in a mouse model of breast cancer Cancer Research. 76: 4646-4646 |
| Farren MR, Shakya R, Hennessey R, et al. (2016) Abstract 2319: Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma Cancer Research. 76: 2319-2319 |
| Elloul S, Chang H, Klebanov B, et al. (2016) Abstract 2219: Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer Cancer Research. 76: 2219-2219 |
| Elloul S, Chang H, Klebanov B, et al. (2016) Abstract 1299: Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumor activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models Cancer Research. 76: 1299-1299 |